ISIKOK-19

N/A

Report date: 2024/11/21 20:00:04

Base Information

Drug NameISIKOK-19

Drug Alias NameISIKOK-19

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTurkey

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAcibadem University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAcibadem University

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A